BRAF mutation in thyroid cancer
Mingzhao Xing(Johns Hopkins University)
Cited by 1,306
Related Papers
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
|Endocrine Reviews|2007|986
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
|Nature Communications|2018|179
BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells
|The Journal of Clinical Endocrinology & Metabolism|2007|124
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
|The Journal of Clinical Endocrinology & Metabolism|2011|105
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer
|Endocrine Related Cancer|2013|102